Table 1.
Clinical characteristics of analyzed patients according to treatment arm
| R2 (n = 122) | R-Chemo (n = 100) | All (N = 222) | P | |
|---|---|---|---|---|
| Age, median (range), y | 60 (33-78) | 60 (30-89) | 60 (30-89) | .90 |
| Males | 65 (53) | 55 (55) | 120 (54) | .89 |
| ECOG PS | .34 | |||
| 0 | 85 (70) | 63 (63) | 148 (67) | |
| 1 | 33 (27) | 36 (36) | 69 (31) | |
| 2 | 3 (2) | 1 (1) | 4 (2) | |
| Not evaluated | 1 (0.8) | 0 (0) | 1 (0.5) | |
| Ann Arbor stage | .47 | |||
| I-II | 3 (2) | 5 (5) | 8 (4) | |
| III-IV | 119 (98) | 95 (95) | 214 (96) | |
| Nodal mass >6 cm | 58 (47) | 52 (52) | 110 (50) | .59 |
| FLIPI score | .46 | |||
| 0-1 | 13 (11) | 6 (6) | 19 (9) | |
| 2 | 48 (39) | 43 (43) | 91 (41) | |
| 3-5 | 60 (49) | 51 (51) | 111 (50) | |
| Missing data | 1 (0.8) | 0 (0) | 1 (0.5) | |
| FLIPI2 score | .73 | |||
| 0-1 | 34 (28) | 24 (24) | 58 (26) | |
| 2 | 37 (30) | 28 (28) | 65 (29) | |
| 3-5 | 50 (41) | 45 (45) | 95 (43) | |
| Missing data | 1 (0.8) | 3 (3) | 4 (2) | |
| Number of peripheral lymph nodes | .23 | |||
| ≤4 | 53 (43) | 52 (52) | 105 (47) | |
| >4 | 69 (57) | 48 (48) | 117 (53) | |
| β2M, mg/L | .67 | |||
| <3 | 75 (61) | 63 (63) | 138 (62) | |
| ≥3 | 45 (37) | 33 (33) | 78 (35) | |
| Missing data | 2 (2) | 4 (4) | 6 (3) | |
| Elevated LDH (>ULN) | .77 | |||
| No | 85 (70) | 73 (73) | 158 (71) | |
| Yes | 36 (30) | 27 (27) | 63 (28) | |
| Missing data | 1 (0.8) | 0 (0) | 1 (0.5) | |
| BM involvement | .43 | |||
| No | 36 (30) | 39 (39) | 75 (34) | |
| Yes | 79 (65) | 58 (58) | 137 (62) | |
| Unspecified | 3 (2) | 1 (1) | 4 (2) | |
| Not done | 4 (3) | 2 (2) | 6 (3) |
Unless otherwise indicated, data are n (%).
β2M, β-2 microglobulin; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; ULN, upper limit of normal.